Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
要約 目的:ポリープ状脈絡膜血管症(PCV)に対し,光線力学療法(PDT)併用アフリベルセプト硝子体注射(IVA)によるmodified treat and extend(mTAE)の1年成績を検討する。
対象と方法:2019年4月〜2020年3月に小沢眼科内科病院を受診した,未治療のPCV症例16例16眼のうち,IVA×3+PDTで導入期治療を行い1年以上経過を追うことができた11例11眼を対象とし,治療前後の視力,中心窩網膜厚,中心窩下脈網膜厚,1年間の注射回数を後ろ向きに検討した。導入期治療として4週ごとに3回連続IVAを施行し,初回のIVAの2日後にPDTを施行した。維持期はmTAEを行い,滲出性変化がなければ投与間隔を4週延長し,滲出性変化があれば4週短縮し,最大投与間隔を12週とした。
結果:治療前の平均logMARは0.32±0.12,12か月後0.11±0.10と有意に改善した(p<0.01)。治療前の中心窩網膜厚は377±48μm,12か月後172±11μmと有意に改善した(p<0.01)。治療前の中心窩下脈絡膜厚は249±33μm,12か月後209±38μmと有意に菲薄化した(p<0.05)。
12か月間でのIVA回数は導入期の3回を含めて平均3.5回(3〜6回)であり,82%の症例で維持期に追加のIVAを必要としなかった。
結論:PCVに対するPDT併用IVAによるmTAE治療は1年後の視力および網膜形態を有意に改善し,また,注射の回数を従来のTAEよりも減らすことができる可能性がある。
Abstract Purpose:This study aimed to report the one-year outcome of combination therapy with intravitreal aflibercept(IVA)and photodynamic therapy(PDT)using a modified treat-and-extend(mTAE)regimen for polypoidal choroidal vasculopathy(PCV).
Cases and method:Eleven eyes with treatment-naïve PCV treated with IVA plus PDT using an mTAE regimen for 1 year between April 2019 and March 2020 were retrospectively reviewed.
We assessed best-corrected visual acuity(BCVA), central foveal thickness(CFT), central choroidal thickness(CCT), and the number of IVA treatments over 1 year.
All patients received three consecutive monthly IVA treatments as loading phase, and PDT was performed 2 days after the first IVA.
During the maintenance phase, the patients were treated using an mTAE regimen.
The injection interval was extended by 4 weeks if there were no exudative changes, or shortened by 4 weeks if any exudative changes were seen. The maximum treatment interval was 12 weeks.
Results:The mean BCVA improved significantly from 0.32±0.12 at baseline to 0.11±0.10 at 1 year(p<0.01). The mean CFT decreased significantly from 377±48 μm at baseline to 172±11 μm at 1 year(p<0.01), while the mean CCT also significantly decreased from 249±33 μm at baseline to 209±38 μm at 1 year(p<0.05). The mean number of IVA treatments was 3.5(3-6)during treatments 1 year. Most(82%)of the patients did not require additional IVA treatments during the maintenance phase.
Conclusion:In this study, combination therapy with IVA and PDT using an mTAE regimen appeared to be effective for patients with treatment-naïve PCV. This therpy may reduce the number of injections compared to conventional TAE.
Copyright © 2021, Igaku-Shoin Ltd. All rights reserved.